Serum Parathyroid Hormone Is a New Potential Risk Factor in Multiple Myeloma
Table 1
Baseline characteristics in MM patients with non-high and high PTH level.
Non-high PTH group (, 93.9%)
High PTH group (, 6.1%)
Gender*
0.017
Male
57 (52.8)
7 (100.0)
Female
51 (47.2)
0 (0.0)
Age*
0.351
>50 years
96 (88.9)
7 (100.0)
≤50 years
12 (11.1)
0 (0.0)
Mean survival (months)
51
29
0.789
Laboratory
PTH
12.5 (0.0–64.9)
91.1 (75.8–284.1)
0.000
Bone marrow-plasma cell (%)
32 (5–90)
44 (24–97)
0.184
Monoclonal protein (g/dL)
4.1 (0.0–8.7)
5.1 (1.9–6.2)
0.539
IgG (mg/dL)
2400 (151–80000)
772 (147–8430)
0.819
IgA (mg/dL)
48.0 (7.0–8630.0)
48.0 (10.0–8750.0)
0.593
IgM (mg/dL)
17.9 (5.3–153.0)
18.0 (17.0–226.0)
0.761
FLC-kappa (mg/L)
32.9 (0.3–62500.0)
27.0 (1.0–67.0)
0.298
FLC-lambda (mg/L)
20.0 (1.0–33900.0)
29.2 (2.8–867.0)
0.734
FLC ratio
2.2 (0.0–13242.4)
0.6 (0.0–16.3)
0.555
Ca (mg/dL)
8.7 (4.0–16.0)
7.9 (7.2–8.6)
0.016
Cr (mg/dL)
1.1 (0.6–12.0)
2.4 (0.7–9.4)
0.062
Hb (g/dL)
9.4 (5.0–15.0)
10.1 (5.7–13.2)
0.734
Albumin (g/dL)
3.1 (1.1–5.1)
3.5 (2.4–4.0)
0.721
2-MG (μg/L)
3981.5 (620.4–80000)
7522.0 (2078.0–33035.5)
0.342
LD (IU/L)
356.0 (85.0–1113.0)
364.0 (239.0–714.0)
0.595
Monoclonal protein type*
0.932
IgG
36 (33.3)
2 (28.6)
IgG
27 (25.0)
1 (14.3)
IgA
20 (18.5)
2 (28.6)
IgA
11 (10.2)
1 (14.3)
Free
4 (3.7)
0 (0.0)
Free
9 (8.3)
1 (14.3)
Not available
1 (0.9)
0 (0.0)
Bone lesion case*
76 (70.4)
5 (71.4)
0.953
Transplantation case*
26 (24.1)
2 (28.6)
0.788
Chromosome abnormality case*
17 (15.7)
1 (14.3)
0.918
0.685
Stage I
25 (23.1)
1 (14.3)
Stage II
39 (36.1)
2 (28.6)
Stage III
44 (40.7)
4 (57.1)
IMWG response*
0.710
CR
23 (21.3)
2 (28.6)
VGPR
8 (7.4)
1 (14.3)
PR
17 (15.7)
0 (0.0)
Progressive disease
47 (43.5)
3 (42.9)
Stable disease
6 (5.6)
1 (14.3)
Not available
7 (6.5)
0 (0.0)
Number of patients (%). Median (range). The reference range of PTH was 15–68.3 pg/mL. We have classified patient cohorts into non-high PTH group and high PTH group based on this criteria. International staging system: I, 2-MG <3500 g/L and albumin ≥3.5 g/dL; II, not fitting stage I or II; stage III, 2-MG ≥5500 g/L. PTH: parathyroid hormone; FLC: serum free light chain; Ca: calcium; Cr: creatinine; Hb: hemoglobin; 2-MG: beta-2 microglobulin; LD: lactate dehydrogenase; : kappa; : lambda; ISS: international staging system; IMWG: international myeloma working group; CR: complete response; VGPR: very good partial response; PR: partial response.
